182 related articles for article (PubMed ID: 25506727)
1. Small molecules for immunomodulation in cancer: a review.
Iyer VV
Anticancer Agents Med Chem; 2015; 15(4):433-52. PubMed ID: 25506727
[TBL] [Abstract][Full Text] [Related]
2. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
3. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
4. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
5. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
6. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
Anari F; Ramamurthy C; Zibelman M
Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
[TBL] [Abstract][Full Text] [Related]
8. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
9. Small Molecular Immune Modulators as Anticancer Agents.
Han Y; Zhu L; Wu W; Zhang H; Hu W; Dai L; Yang Y
Adv Exp Med Biol; 2020; 1248():547-618. PubMed ID: 32185725
[TBL] [Abstract][Full Text] [Related]
10. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.
Drenckhan A; Freytag M; Supuran CT; Sauter G; Izbicki JR; Gros SJ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1024-1033. PubMed ID: 29865880
[TBL] [Abstract][Full Text] [Related]
11. Tricking the balance: NK cells in anti-cancer immunity.
Pahl J; Cerwenka A
Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
[TBL] [Abstract][Full Text] [Related]
12. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
[TBL] [Abstract][Full Text] [Related]
13. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
15. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
16. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
17. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
18. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response.
PeÑarando J; Aranda E; RodrÍguez-Ariza A
Transl Res; 2019 Aug; 210():99-108. PubMed ID: 30953610
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
